For pet owners across the United States, the label on a bag of kibble is often the primary source of truth. Consumers rely on the assumption that federal oversight ensures these products are safe, accurately described, and manufactured to high standards. However, Susan Thixton, a prominent pet food consumer advocate and founder of TruthaboutPetFood.com, argues that this trust is misplaced. Through a series of persistent inquiries, legal petitions, and public advocacy, Thixton has exposed a pattern of silence and evasion from the U.S. Food and Drug Administration (FDA)—an agency mandated by the Federal Food, Drug, and Cosmetic (FD&C) Act to protect the health of companion animals.
The Mandate vs. The Reality
The FDA’s own digital presence asserts that the FD&C Act requires all animal foods to be "safe to eat, produced under sanitary conditions, contain no harmful substances, and be truthfully labeled." This mandate is the cornerstone of consumer protection in the pet industry. Yet, as Thixton’s recent documentation reveals, the agency’s performance regarding enforcement—particularly concerning labeling accuracy—remains deeply contested.
The core of the conflict lies in the definition of "truthful labeling." When a consumer purchases a product like Meow Mix Original Choice, the packaging features vivid, high-quality imagery of grilled chicken breast, roasted turkey, and fresh fish fillets. However, the ingredient list paints a markedly different picture, identifying these components as "chicken by-product meal," "turkey by-product meal," and "fish meal."
For years, advocates have challenged the FDA to explain how imagery depicting human-grade, whole-muscle meats can be reconciled with the reality of processed, rendered meals. Despite multiple formal requests sent on January 28, 2026, and follow-up correspondence on March 12, 2026, the FDA has maintained a policy of total silence. As of September 15, 2026, the agency has failed to provide a single justification for why these marketing practices are permitted under federal law.
A Chronology of Evasion
The breakdown in communication between consumer advocacy groups and the FDA is not an isolated event; it represents a systemic issue spanning years of inquiries.
The Labeling Controversy (2026)
- January 28, 2026: Inquiry submitted to the FDA regarding the misleading nature of packaging imagery on popular cat food brands. The agency provided no response.
- March 12, 2026: Follow-up inquiry regarding the lack of response. Again, the FDA remained silent.
The Mystery of "Tankage" (2026)
- July 6, 2026: Thixton requested clarification on the labeling of "tankage"—a product resulting from the processing of condemned materials in USDA-inspected slaughterhouses. The inquiry sought to understand if this material, when included in pet food, must be explicitly labeled as such or if it is permitted to be hidden under generic labels like "chicken meal." The FDA declined to answer.
The Avian Flu Information Gap (2025–2026)
- September 15, 2025: A critical inquiry was launched regarding the FDA’s communication strategy surrounding Highly Pathogenic Avian Influenza (HPAI). While the FDA issued multiple alerts focusing on raw pet food, data suggests that only 4% of diagnosed feline cases were linked to raw diets. Advocates questioned the safety of kibble and the risks to outdoor cats. The FDA has yet to provide the requested breakdown of data, leaving pet owners without the full context needed to assess risks to their pets.
The AAFCO Modernization Disconnect (2025–2026)
- May 29, 2025: Following the FDA’s decision to terminate its long-standing relationship with the Association of American Feed Control Officials (AAFCO), advocates sought clarity on the future of the "Pet Food Label Modernization" initiative.
- June 2025: The FDA responded, but only by referring the inquirer to a generic link regarding the expiration of their Memorandum of Understanding with AAFCO. The link contained no information on the modernization project.
- June 5, 2026: A follow-up request was sent, pointing out the irrelevance of the provided link. The FDA responded by doubling down on their previous, non-responsive answer.
The Citizen Petition: A Battle of Time
Perhaps the most egregious example of bureaucratic stalling occurred regarding a formal Citizen Petition filed in 2022. This legal mechanism is designed to force an agency to respond to public concerns within 180 days. Instead, the FDA took 1,333 days to issue a response—and when they finally did, the answer was a flat refusal to enforce the requested standards.
On April 13, 2026, a Petition for Reconsideration was filed, providing further evidence of consumer deception and requesting a response within 45 days. As of September 15, 2026, the FDA has ignored this request for 155 days.
Implications: The Erosion of Consumer Trust
The implications of this institutional silence are significant. When a regulatory body stops engaging with the public, it creates a vacuum of accountability.
The "Truthful Labeling" Crisis
If companies are allowed to use imagery that implies high-quality ingredients while utilizing industrial by-products, the market loses its ability to function based on informed consent. Consumers who believe they are purchasing high-protein, whole-food products for their pets may be unwittingly paying premium prices for rendered materials, with no regulatory recourse.
Public Health Risks
The lack of transparency regarding HPAI is particularly alarming. By focusing exclusively on raw pet food while failing to disclose data regarding kibble-fed or outdoor-access cats, the FDA may be inadvertently steering owners toward a false sense of security. If the majority of diagnosed cases are appearing in populations not associated with raw food, the agency’s current public alerts may be failing to warn the public of the most prevalent risks.
The Collapse of Collaborative Governance
The FDA’s retreat from AAFCO, followed by its refusal to clarify the future of labeling modernization, creates a "regulatory no-man’s-land." Manufacturers, retailers, and consumers are left in a state of uncertainty. If federal standards are not being modernized and the agency is refusing to comment on the implementation of new guidelines, the industry risks becoming fragmented, with label accuracy varying wildly between states and manufacturers.
Moving Forward: The Role of Advocacy
The persistent silence from the FDA underscores the vital importance of third-party advocacy. Organizations like the Association for Truth in Pet Food and portals like TruthaboutPetFood.com serve as essential watchdogs. By maintaining lists of trusted manufacturers and continuing to push for transparency, these groups act as the primary buffer between the consumer and a regulatory system that appears increasingly detached from its core responsibilities.
For the average pet owner, the message is clear: reliance on regulatory oversight alone is insufficient. Until the FDA demonstrates a commitment to transparency and fulfills its legal obligations to address consumer concerns, the responsibility for verifying product quality falls largely on the purchaser.
The ongoing, unanswered questions of 2026 represent a critical juncture. Whether through the courts, public pressure, or continued legislative lobbying, the demand for accountability remains undiminished. As Thixton noted in her recent communications, "We WILL continue to ask them for answers."
Ultimately, the goal is not merely to obtain a response, but to force a structural change in how the FDA views its relationship with the people—and the pets—it is supposed to serve. A truly "truthful" label is not just a regulatory requirement; it is a fundamental aspect of the contract between pet food manufacturers and the families who trust them. When that contract is compromised by regulatory neglect, the health of the nation’s pets remains in the balance.
